SEARCH

SEARCH BY CITATION

References

  • 1
    Mangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002; 112: 55665.
  • 2
    Voutilainen S, Lakka TA, Hämelahti P, Lehtimäki T, Poulsen HE, Salonen JT. Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. J Intern Med 2000; 248: 21722.
  • 3
    Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 919.
  • 4
    Knekt P, Reunanen A, Alfthan G et al. Hyperhomocystinemia. A risk factor or a consequence of coronary heart disease? Arch Intern Med 2001; 161: 158994.
  • 5
    Woo KS, Chook P, Lolin Y et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 25424.
  • 6
    Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 104250.
  • 7
    Glueck CJ, Shaw P, Land JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 1326.
  • 8
    Schlaich MP, John S, Jacobi J, Lackner KJ, Schmieder RE. Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. Atherosclerosis 2000; 153: 3839.
  • 9
    Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002; 22: 10425.
  • 10
    O'Callaghan P, Meleady R, Fitzgerald T, Graham I, the European COMAC group. Smoking and plasma homocysteine. Eur Heart J 2002; 23: 15806.
  • 11
    Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67: 26370.
  • 12
    Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 202633.
  • 13
    Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988; 20: 4650.
  • 14
    Schwab U, Törrönen A, Toppinen L et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 2002; 76: 9617.
  • 15
    Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 80311.
  • 16
    Salonen JT, Salonen R, Seppänen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfraction, and the risk of acute myocardial infarction: a prospective population study in eastern Finnish men. Circulation 1991; 84: 12939.
  • 17
    Salonen JT, Seppänen K, Nyyssönen K et al. Intake of mercury from fish, lipid peroxidation and the risk of myocardial infarction and coronary, cardiovascular and any death in eastern Finnish men. Circulation 1995; 91: 64555.
  • 18
    Vollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001; 74: 1306.
  • 19
    Bostom AG, Silbershatz H, Rosenberg IH et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingam men and women. Arch Intern Med 1999; 159: 107780.
  • 20
    Blacher J, Benetos A, Kirzin JM, Malejac A, Guize L, Safar ME. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002; 90: 5915.
  • 21
    Greenland S. Modelling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 3409.
  • 22
    Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 17007.
  • 23
    Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 95663.
  • 24
    Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002; 53: 53849.
  • 25
    Chowienczyk PJ, Watts GF, Cockkroft JR, Ritte JM. Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolemia. Lancet 1992; 340: 14302.
  • 26
    Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496500.
  • 27
    Vaudo G, Marchesi S, Siepi D et al. Relevance of homocysteine on brachial flow-mediated vasodilatation and carotid and femoral intima-media thickness in patients with hypercholesterolemia. Am J Cardiol 2004; 93: 14136.
  • 28
    Mannucci PM. Recent progress in the pathophysiology of fibrinogen. Eur Heart J 1995; 16: 2530.
  • 29
    Norio R. Diseases in Finland and Scandinavia. In: RothscildHR, ed. Biocultural Aspects of Disease. Orlando, FL: Academic Press Inc., 1981; 358415.
  • 30
    Brattström L, Wilcken DEL, Öhrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis. Circulation 1998; 98: 25206.
  • 31
    Rady PL, Tyring SK, Hudnall SD et al. Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am J Med Genet 1999; 86: 3804.